Niagen for COVID-19

Phase-Based Estimates
Clinical Translational Research Unit, Boston, MA
COVID-19+4 More
Niagen - Drug
All Sexes
Eligible conditions

Study Summary

This study is evaluating whether a dietary supplement may help improve cognition for individuals who have been infected with the COVID-19 virus for at least 2 months.

See full description

Eligible Conditions

  • COVID-19
  • Neurobehavioral Manifestations
  • Sequelae of; Infection
  • Symptoms, Cognitive
  • Covid19

Treatment Effectiveness

Effectiveness Estimate

3 of 3
This is better than 93% of similar trials

Study Objectives

This trial is evaluating whether Niagen will improve 1 primary outcome and 3 secondary outcomes in patients with COVID-19. Measurement will happen over the course of Baseline and every 5 weeks for 22 weeks.

Week 22
Examine the effect of Niagen in COVID-related physical symptoms
Examine the effect of Niagen in anxiety symptoms
Examine the effect of Niagen in depression symptoms
Week 22
Examine the effect of Niagen on cognitive functioning as measured by executive functioning and memory composite scores.

Trial Safety

Safety Estimate

3 of 3
This is better than 85% of similar trials

Trial Design

2 Treatment Groups

Placebo group

This trial requires 100 total participants across 2 different treatment groups

This trial involves 2 different treatments. Niagen is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.

Supplement: 60 participants will take Niagen 2000mg in the form of capsules daily.
Placebo: 40 participants will take placebo in the form of a capsule.

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 12 and 22 weeks
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly baseline, 12 and 22 weeks for reporting.

Who is running the study

Principal Investigator
E. G.
Edmarie Guzman-Velez, Instructor
Massachusetts General Hospital

Closest Location

Clinical Translational Research Unit - Boston, MA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 6 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
At least two neurological and/or physical symptoms that started at COVID-19 infection and are ongoing at study entry, including fatigue, weakness, headache, loss of smell, tingling/numbness, shortness of breath, loss of appetite, palpitations/tachycardia, hair loss, musculoskeletal and/or chest pain;
History of SARS-CoV-2 PCR+ at least 2 months prior to study entry;
SARS-CoV-2 negative (PCR) at study entry;
Persistent cognitive difficulties (esp. "brain fog") that began around the time of the acute COVID-19;
Willing and able to consent, complete all assessment and study procedures;
Not pregnant or lactating.

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can covid-19 be cured?

Add answer

Though the disease can be self-limited, there is no cure for SARS. The risk is highly probable that more cases will be reported in China, thus posing a public health concern for SARS. In addition, the disease could be self-limited in patients with SARS with timely healthcare after the initial self-limited phase.

Unverified Answer

What are common treatments for covid-19?

Add answer

Antibiotics are used widely, and antiviral and immunomodulatory therapies are also used often in conjunction with the use of anti-viral drugs. In the cases of severe and lethal infections, convalescent treatment also becomes necessary.

Unverified Answer

What is covid-19?

Add answer

Covid-19 is an infectious disease originating from viruses in the genus coronavirus and in particular the SARS-CoV-2. It can be contracted through the air, by close contact with an infected individual in China, or through an contaminated food, beverage, or animal source. On May 4, the CDC announced its preliminary recommendation that those with chronic lung disease, including those who have undergone a lobectomy, should not travel to or from Wuhan. On June 21, the CDC updated these recommendations based on a review of more recent information, including the existence of 14th case of asymptomatic infections.

Unverified Answer

What causes covid-19?

Add answer

While we do not know what causes SARS or MERS, we do know that the viruses have a number of different mutations and are susceptible to various treatments. Future work will have to decide how to test the hypotheses that the viruses are replicating in the blood, saliva or body fluids and that antibodies are present.

Unverified Answer

How many people get covid-19 a year in the United States?

Add answer

An estimated 10,000 cases of covid-19 are diagnosed per year in the United States. Most of these cases are in individuals older than 50 years; a smaller number of cases occurs in adults, but they occur at much lower rates.

Unverified Answer

What are the signs of covid-19?

Add answer

Results from a recent paper, we confirmed, the patient’s demographics had a greater impact on death risk. Female subjects were more likely to die from Coronavirus pneumonia. There wasn’t a difference between the genders’ rates from other diseases. Age proved to be a significant predictor of mortality, for both genders. More importantly, however, males were twice as likely to die from other diseases as females. If an incubation period of 2-14 days is assumed, the patient was between 65% to 80% likely to die.

Unverified Answer

What is the primary cause of covid-19?

Add answer

The cause of covid-19 is likely multiple, with no single agent being responsible for the large majority of infections in the first 2 weeks of the month of February 2020. This may reflect the spread of the virus within healthcare settings. The rapid dissemination of the virus suggests a new pandemic strain with an inherent ability to rapidly adapt in the human host. Further surveillance is warranted to determine whether the virus persists over longer periods of time.

Unverified Answer

Does covid-19 run in families?

Add answer

The familial clustering of AICD, COPD or diabetes in our sample was not observed. The family history of MI or CAD in siblings was seen in 10.8% of families. There were no major trends in COVID-19 risk factors associated with siblings history of MI, COPD or diabetes.

Unverified Answer

Is niagen typically used in combination with any other treatments?

Add answer

NIg is the treatment most frequently used together with chemotherapy for patients who have advanced solid tumours. More studies should focus on the best combination of drugs and how this combination may relate to treatment outcome.

Unverified Answer

What are the common side effects of niagen?

Add answer

These side effects and their severity in children and adolescents seem to be related to age and dosage. The use of nickel plating might be a potential cause of [allergy]( or allergic sensitization in children, but the risk appears to be very low and may not justify the use of nickel at lower plasma concentrations than recommended by the manufacturer. In older people, hypersensitivity with nickel has been described. This may be associated with a history of previous allergic reactions.

Unverified Answer

What does niagen usually treat?

Add answer

This information should be used as a basic tool for medical professionals to understand and handle patients' cases that need special attention at their clinic. The information will also help people with multiple diseases to take their medication. In conclusion, Niagen treatment always relieves symptoms from patients with a variety of disease, most especially, in patients with multiple diseases/problems.

Unverified Answer

What are the latest developments in niagen for therapeutic use?

Add answer

The field of Niagen research has been incredibly productive with many new small molecules being in clinic testing. As of February 24 the WHO had announced a temporary delay of the therapeutic use of Niagen in humans because of the global situation as well as the need to take a more deliberate strategy in terms of patient selection. The field of Niagen research has continued to be productive and has a number of new small molecules in clinical trials and a number of small molecule combination studies. The first Niagen human trials will almost certainly not be feasible for a full month or more. Findings from a recent study regarding Niagen for acute lung injury as well as Niagen in chronic obstructive pulmonary disease are promising and are demonstrating the potential clinical utility of Niagen in these rare diseases.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for COVID-19 by sharing your contact details with the study coordinator.